https://www.zacks.com/stock/news/2247009/here-s-why-gsk-gsk-gained-but-lagged-the-market-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2247009
Mar 27, 2024 - GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.
zc:776169638357304846
0
https://www.zacks.com/stock/news/2246577/aeterna-zentaris-aezs-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2246577
Mar 27, 2024 - AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
zc:-561238193720563043
0
https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352
Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
zc:9206332608251634855
0
https://www.zacks.com/stock/news/2245649/equillium-inc-eq-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2245649
Mar 25, 2024 - Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
zc:2783272519852810513
0
https://www.zacks.com/stock/news/2245610/gsk-or-tech-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2245610
Mar 25, 2024 - GSK vs. TECH: Which Stock Is the Better Value Option?
zc:7712366103963193695
0
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
zc:-5021796422199526666
0
https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568
Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
zc:-9033398220000923449
0
https://www.zacks.com/stock/news/2243108/gsk-gsk-increases-yet-falls-behind-market-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243108
Mar 19, 2024 - In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.
zc:3031650112934949121
0
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
zc:-2740657310709623932
0
https://www.zacks.com/stock/news/2242368/immuneering-imrx-plummets-71-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2242368
Mar 18, 2024 - Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
zc:-195634279698284911
0